Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene is a clinical-stage biotechnology company with a differentiated product portfolio of genetic medicines for rare neurological diseases. With a focus on safety and efficacy, the company's proprietary technology, EXACT, has shown potential in treating Rett syndrome and CLN5 Batten disease. The recent completion of a $135M financing extends cash runway into 2029, while the initiation of a Process Performance Qualification campaign and plans for commercial readiness activities show strong execution. The upcoming readout of 12-month data from the Embolden trial in 2027 and NGN-401's potential over competitor TSHA-102 should drive further valuation catch-up.

Bears say

Neurogene is currently a clinical-stage biotechnology company with a strong balance sheet and enough cash on hand to execute their pivotal readout without needing to raise additional funds. However, the upcoming mid-2026 Phase 1/2 update for their lead drug candidate NGN-401, targeting Rett syndrome, will be a key catalyst as investors will be focused on the durability and change in function over time. While the Phase 1/2 data has been promising, with no skills lost and multi-domain gains, the 12+ month follow-up for all 10 participants will be closely watched to see if the initial gains persist and translate into daily function.

Neurogene Inc (NGNE) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Neurogene Inc (NGNE) has a Strong Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.